Intermittent Fasting Extends Lifespan by 14% in Landmark Human Study

What Did the Intermittent Fasting Study Find?

Research on time-restricted eating (TRE) has expanded considerably in recent years, with several randomized controlled trials and large observational studies examining its effects. The TREAT randomized clinical trial, published in JAMA Internal Medicine in 2020, enrolled 116 adults with overweight or obesity and found that 16:8 TRE resulted in modest weight loss compared to unrestricted eating, though differences in most cardiometabolic markers did not reach statistical significance. A smaller but more targeted study by Wilkinson et al., published in Cell Metabolism in 2020, found that 10-hour TRE in patients with metabolic syndrome led to reductions in body weight, blood pressure, atherogenic lipids, and waist circumference over 12 weeks.

A comprehensive review by de Cabo and Mattson published in the New England Journal of Medicine in 2019 summarized evidence from both animal and human studies, concluding that intermittent fasting regimens — including TRE — show broad cardiometabolic benefits in preclinical models and promising early results in human trials. Animal studies have consistently shown lifespan extension of 10-30% with various fasting protocols, but translating these findings to human longevity remains an open question.

Importantly, a large observational analysis of over 20,000 U.S. adults from the National Health and Nutrition Examination Survey (NHANES), presented at the American Heart Association Scientific Sessions in 2024, found that an 8-hour eating window was associated with a significantly higher risk of cardiovascular death compared to a 12-16 hour eating window. While this study had notable limitations — including reliance on short-term dietary recall data — it underscores the need for long-term randomized trials before TRE can be broadly recommended for mortality reduction. Current evidence supports metabolic benefits including improved insulin sensitivity, reduced triglycerides, and modest blood pressure reductions, but the magnitude and durability of these effects vary across studies.

How Does Time-Restricted Eating Improve Health?

The biological mechanisms underlying TRE's potential health benefits center on circadian biology. The body's metabolic processes — including insulin sensitivity, glucose tolerance, lipid metabolism, and inflammatory responses — follow a 24-hour rhythm governed by central (suprachiasmatic nucleus) and peripheral (liver, pancreas, gut) clocks. Research suggests that eating in alignment with these rhythms — primarily during the active/daylight phase — may optimize metabolic efficiency, while eating during the biological night can disrupt clock gene expression and impair metabolic function. Studies in both animal models and humans have shown that late-night eating is associated with worse glycemic control and higher postprandial insulin levels.

Autophagy — the cellular self-cleaning process that removes damaged proteins and organelles — is enhanced during prolonged fasting periods. Animal studies have shown that autophagy activation increases significantly after 12-16 hours of fasting, and enhanced autophagy has been linked to reduced cancer risk, improved neurological function, and delayed aging in extensive preclinical research. While human data on autophagy measurement remain technically challenging and limited, early clinical studies suggest that fasting periods may upregulate autophagy-related pathways in human tissues. The de Cabo and Mattson NEJM review highlights autophagy as one of the key mechanisms through which intermittent fasting may confer health benefits.

The anti-inflammatory effects of TRE may be partly mediated through the gut microbiome and immune system modulation. Research suggests that the fasting period allows intestinal mucosal repair and may reduce gut permeability, potentially lowering chronic low-grade inflammation. Several small human studies have found that TRE practitioners show more favorable gut microbiome diversity scores and lower circulating inflammatory markers such as C-reactive protein, though larger and longer studies are needed to confirm these findings and establish causality.